Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A

Blood

Volumn 124, Issue 23, 2014, Pages 3398-3408

  Calvez, Thierry ^a,b   Chambost, Hervé ^c,d   Claeyssens Donade, Ségolène ^e   D'Oiron, Roseline ^f   Goulet, Véronique ^g   Guillet, Benoît ^h   Héritier, Virginie ^g   Milien, Vanessa ^c   Rothschild, Chantal ⁱ   Roussel Robert, Valérie ^j   Vinciguerra, Christine ^k   Goudemand, Jenny ^l  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^c TIMONE HOSPITAL   (France)

^d INSERM   (France)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f BICÊTRE HOSPITAL   (France)

^g French Institute for Public Health Surveillance   (France)

^h RENNES UNIVERSITY HOSPITAL   (France)

ⁱ Section of Radiology   (France)

^j Universit é de Lyon ^*  (France)

^k University Lyon 1   (France)

^l LILLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; F8 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ANTIBODY PRODUCTION; COHORT ANALYSIS; FRANCE; HEMOPHILIA A; HUMAN; IMMUNOLOGY; INFANT; MALE; META ANALYSIS (TOPIC); POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX;

ANTIBODY FORMATION; CHILD, PRESCHOOL; COHORT STUDIES; FACTOR VIII; FRANCE; HEMOPHILIA A; HUMANS; INFANT; MALE; META-ANALYSIS AS TOPIC; PRODUCT SURVEILLANCE, POSTMARKETING; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX;

EID: 84914140043     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-586347     Document Type: Article

References (46)

1. Hoyer LW. Hemophilia A. N Engl J Med. 1994; 330(1):38-47.
2. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet. 2012;379(9824):1447-1456.
3. Darby SC, Keeling DM, Spooner RJD, et al; UK Haemophilia Centre Doctors' Organisation. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost. 2004;2(7):1047-1054.
4. Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). Br J Haematol. 2000;111(1):78-90.
5. Teitel JM, Sholzberg M. Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies. Blood Rev. 2013;27(2):103-109.
6. Di Minno MN, Di Minno G, Di Capua M, Cerbone AM, Coppola A. Cost of care of haemophilia with inhibitors. Haemophilia. 2010;16(1):e190-e201.
7. Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost. 2010; 8(6):1256-1265.
8. Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol. 2012;81(1): 82-93.
9. Astermark J, Altisent C, Batorova A, et al; European Haemophilia Therapy Standardisation Board. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia. 2010;16(5):747-766.
10. Gouw SC, Fijnvandraat K. Identifying nongenetic risk factors for inhibitor development in severe hemophilia a. Semin Thromb Hemost. 2013;39(7): 740-751.
11. Gouw SC, van den Berg HM, Fischer K, et al; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121(20): 4046-4055.
12. Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood. 2007;109(11):4693-4697.
13. Mancuso ME, Mannucci PM, Rocino A, Garagiola I, Tagliaferri A, Santagostino E. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A. J Thromb Haemost. 2012;10(5):781-790.
14. Gouw SC, van der Bom JG, Ljung R, et al; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368(3): 231-239.
15. Iorio A, Skinner MW, Makris M. Factor VIII products and inhibitors in severe hemophilia A. N Engl J Med. 2013;368(15):1456.
16. Kessler CM, Iorio A. The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters. Haemophilia. 2013;19(3):351-354.
17. European Medicines Agency. Kogenate Bayer and Helixate NexGen. http://www.ema.europa.eu/ema/index.jsp?curl5pages/medicines/human/referrals/Kogenate-Bayer-and-Helixate-NexGen/human-referral-prac-000022.jsp.Accessed July 1, 2014.
18. Calvez T, Biou M, Costagliola D, et al; Suivi Thérapeutique National des Hémophiles Group. The French haemophilia cohort: rationale and organization of a long-term national pharmacosurveillance system. Haemophilia. 2001;7(1):82-88.
19. Kempton CL, White GC II. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood. 2009;113(1):11-17.
20. D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med. 1990;9(12):1501-1515.
21. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815-2834.
22. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
23. Giangrande PLF; KOGENATE Bayer Study Group. Safety and efficacy of KOGENATE Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). Haemophilia. 2002;8(Suppl 2):19-22.
24. Kreuz W, Gill JC, Rothschild C, et al; International Kogenate-FS Study Group. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost. 2005;93(3):457-467.
25. Musso R, Santagostino E, Faradji A, et al; KOGENATE Bayer European PMS Study Group. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost. 2008;99(1):52-58.
26. Delumeau J-C, Ikegawa C, Yokoyama C, Haupt V. An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A. Thromb Haemost. 2008; 100(1):32-37.
27. Stonebraker JS, Bolton-Maggs PHB, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia. 2010;16(1):20-32.
28. Kasper CK, Lin JC. Prevalence of sporadic and familial haemophilia. Haemophilia. 2007;13(1): 90-92.
29. Gouw SC, van den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood. 2012;119(12): 2922-2934.
30. Hay CR, Ollier W, Pepper L, et al; UKHCDO Inhibitor Working Party. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. Thromb Haemost. 1997;77(2):234-237.
31. Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost. 1997;77(2): 238-242.
32. Pavlova A, Delev D, Lacroix-Desmazes S, et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost. 2009;7(12):2006-2015.
33. Lozier JN, Rosenberg PS, Goedert JJ, Menashe I. A case-control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A. Haemophilia. 2011;17(4): 641-649.
34. Astermark J, Donfield SM, Gomperts ED, et al; Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood. 2013;121(8): 1446-1454.
35. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109(11):4648-4654.
36. Lusher JM, Scharrer I. Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer. Int J Hematol. 2009;90(4):446-454.
37. Preston RJS, Rawley O, Gleeson EM, O'Donnell JS. Elucidating the role of carbohydrate determinants in regulating hemostasis: insights and opportunities. Blood. 2013;121(19): 3801-3810.
38. Dasgupta S, Navarrete A-M, Bayry J, et al. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proc Natl Acad Sci USA. 2007;104(21): 8965-8970.
39. Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med. 2009;360(16):1618-1627.
40. Schwarz J, Astermark J, Menius ED, et al; Hemophilia Inhibitor Genetics Study Combined Cohort. F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia. 2013; 19(1):113-118.
41. Pahl S, Pavlova A, Driesen J, Müller J, Pötzsch B, Oldenburg J. In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile. Haemophilia. 2013;19(3):392-398.
42. van der Bom JG, Gouw SC, Rosendaal FR. Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A. Haemophilia. 2014;20(2): e171-e174.
43. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia. 2007;13(Suppl 5):65-68.
44. Soucie JM, Miller CH, Kelly FM, et al; Haemophilia Inhibitor Research Study Investigators. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia. 2014;20(2):230-237.
45. Makris M, Calizzani G, Fischer K, et al. EUHASS: The European Haemophilia Safety Surveillance system. Thromb Res. 2011;127(Suppl 2):S22-S25.
46. Fischer K, Lewandowski D, Marijke van den Berg H, Janssen MP. Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project. Haemophilia. 2012; 18(3):e241-e246.